Opthea Ltd. ADR (OPT): Price and Financial Metrics
OPT Price/Volume Stats
| Current price | $3.40 | 52-week high | $4.42 |
| Prev. close | $3.40 | 52-week low | $1.60 |
| Day low | $3.39 | Volume | 2,694 |
| Day high | $3.44 | Avg. volume | 24,564 |
| 50-day MA | $3.48 | Dividend yield | N/A |
| 200-day MA | $2.72 | Market Cap | 198.54M |
OPT Stock Price Chart Interactive Chart >
Opthea Ltd. ADR (OPT) Company Bio
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.
Latest OPT News From Around the Web
Below are the latest news stories about OPTHEA LTD that investors may wish to consider to help them evaluate OPT as an investment opportunity.
Opthea to Receive US$35M Commitment and Additional US$50M FundingOpthea to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and its life science franchise Abingworth, as well as a further US$50m financing under an Amended DFA to include a new co-investor This financing is non-dilutive to shareholders, with no equity issued to Carlyle, Abingworth or the new co-investor Investment driven by the potential of sozinibercept (OPT-302) to provide superior visual outcomes for wet AMD patients and to provide a multi-billion d |
Opthea Receives A$8.8 million R&D Tax IncentiveMELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.8 million (US$5.9 million) research and development (R&D) tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2022/2023 financial year, and represents the amount d |
Opthea to Present at the FLORetina 2023 CongressMELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy. Professor Angelo Maria Minnella, MD from the Department of Ophthalmology, Catholic Unive |
Opthea to Present at the Jefferies 2023 London Healthcare ConferenceMELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Founder and Chief Innovation Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference being held on November 14th -16th, 2023. Dr. Baldwin’s fireside chat with Jefferies Analyst, Kelly Shi |
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) ConferenceMELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Founder & Chief Innovation Officer, will present at Eyecelerator which is part of AAO 2023 being held in San Francisco, CA on November 3rd to 6th, 2023. Dr. Baldwin will present on Thursday, November 2nd at 1:36pm PST as p |
OPT Price Returns
| 1-mo | 0.29% |
| 3-mo | 22.74% |
| 6-mo | 112.50% |
| 1-year | -4.22% |
| 3-year | -62.05% |
| 5-year | N/A |
| YTD | 15.25% |
| 2023 | -44.96% |
| 2022 | -28.96% |
| 2021 | -32.72% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...